[go: up one dir, main page]

LV12438B - METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START - Google Patents

METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START Download PDF

Info

Publication number
LV12438B
LV12438B LVP-99-134A LV990134A LV12438B LV 12438 B LV12438 B LV 12438B LV 990134 A LV990134 A LV 990134A LV 12438 B LV12438 B LV 12438B
Authority
LV
Latvia
Prior art keywords
apo
quot
thc
mice
stigmastanol
Prior art date
Application number
LVP-99-134A
Other languages
English (en)
Latvian (lv)
Other versions
LV12438A (en
Inventor
Egon Novak
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of LV12438A publication Critical patent/LV12438A/xx
Publication of LV12438B publication Critical patent/LV12438B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-99-134A 1997-12-18 1999-09-17 METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START LV12438B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (2)

Publication Number Publication Date
LV12438A LV12438A (en) 2000-03-20
LV12438B true LV12438B (en) 2000-09-20

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-134A LV12438B (en) 1997-12-18 1999-09-17 METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START

Country Status (18)

Country Link
US (1) US5985936A (no)
EP (1) EP0967982A2 (no)
CN (1) CN1252724A (no)
AU (1) AU1656099A (no)
BG (1) BG103740A (no)
BR (1) BR9807577A (no)
CA (1) CA2281710A1 (no)
EE (1) EE9900354A (no)
GE (1) GEP20022783B (no)
HU (1) HUP0100737A3 (no)
LT (1) LT4801B (no)
LV (1) LV12438B (no)
MD (1) MD1920F2 (no)
NO (1) NO993979L (no)
PL (1) PL335421A1 (no)
RU (1) RU2173151C2 (no)
SK (1) SK112999A3 (no)
WO (1) WO1999032097A2 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
US6610320B2 (en) 2000-04-14 2003-08-26 Mars, Incorporated Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
EP1442133B1 (en) * 2001-02-12 2007-12-12 N.V. Organon Use of Mirtazapine for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2005208566A1 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. APOE genetic markers associated with age of onset of Alzheimer's Disease
WO2006068768A2 (en) * 2004-11-24 2006-06-29 Hanna Skubatch Methods and compositions for treating conditions
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
EP2254580A1 (en) * 2008-03-27 2010-12-01 EVOTEC Neurosciences GmbH Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
WO2012149111A1 (en) * 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
EP3681477A4 (en) 2017-09-14 2021-06-09 Phoenix Biotechnology, Inc. PROCEDURES AND IMPROVED COMPOSITION FOR TREATMENT OF TREITERPEN RESPONSIBLE CONDITIONS, DISEASES, OR DISORDERS
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
EP4081198A1 (en) 2019-12-24 2022-11-02 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
TJ302B (en) * 1994-09-29 2001-08-06 Univ British Columbia A process for isolating a phytosterol composition composition a product therapeutically
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
US6939570B1 (en) * 1997-05-15 2005-09-06 University Of Washington Composition and methods for treating Alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
EP0967982A2 (en) 2000-01-05
PL335421A1 (en) 2000-04-25
LV12438A (en) 2000-03-20
GEP20022783B (en) 2002-09-25
NO993979L (no) 1999-10-13
BG103740A (en) 2000-05-31
EE9900354A (et) 2000-02-15
CA2281710A1 (en) 1999-07-01
WO1999032097A3 (en) 1999-09-02
HUP0100737A3 (en) 2002-07-29
US5985936A (en) 1999-11-16
MD1920F2 (ro) 2002-05-31
WO1999032097A2 (en) 1999-07-01
BR9807577A (pt) 2001-08-07
AU1656099A (en) 1999-07-12
MD990262A (en) 2000-06-30
HUP0100737A2 (hu) 2001-09-28
CN1252724A (zh) 2000-05-10
SK112999A3 (en) 2001-11-06
NO993979D0 (no) 1999-08-18
RU2173151C2 (ru) 2001-09-10
LT4801B (lt) 2001-06-25
LT99114A (lt) 2001-01-25

Similar Documents

Publication Publication Date Title
LV12438B (en) METHOD AND COMPOSITION TO AVOID ALCHEIMER'S DISEASE AND REMOVE ITS START
KR101331658B1 (ko) 오메가-3 및 오메가-6 지방산을 함유하는 글리세로인지질
US20130337041A1 (en) Charged phospholipid compositions and methods for their use
JP2004505910A (ja) アポリポタンパク質ｅ分泌を誘導するための方法
Yabuki et al. Dehydroepiandrosterone administration improves memory deficits following transient brain ischemia through sigma-1 receptor stimulation
Azzi The role of α-tocopherol in preventing disease
JPH10504037A (ja) 内毒素関連疾患の予防および治療に用いられる方法および組成物
Dragan et al. Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?
Yasamineh et al. Potential use of the cholesterol transfer inhibitor U18666A as a potent research tool for the study of cholesterol mechanisms in neurodegenerative disorders
AU2006284990B2 (en) Method for treatment or prevention of conditions caused by gram-positive bacteria
Mukherjee et al. Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum
Chen et al. Methylated urolithin A, mitigates cognitive impairment by inhibiting NLRP3 inflammasome and ameliorating mitochondrial dysfunction in aging mice
EP1830829B1 (en) Sphingolipids in treatment and prevention of hepatic steatosis
RU2631887C2 (ru) Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения демиелинизирующих заболеваний живого организма, включая профилактику заболевания
Oestereich The cholesteryl ester transfer protein in Alzheimer's disease
Liu et al. Myricetin alleviates high-fat diet-induced atherosclerosis in ApoE-/-mice by regulating bile acid metabolism involved in gut microbiota remodeling
MXPA99007622A (en) Method of preventing and delaying the onset of alzheimer's disease and composition therefor
CZ9902921A3 (cs) Léčivo pro profylaxi nebo zpomalení rozvoje Alzheimerovy choroby a terapeuticky účinný produkt k prevenci Alzheimerovy choroby
JP2001512494A (ja) アルツハイマー病を予防するまたはその発病を遅延させる方法およびそのための組成物
Farooqui et al. Neurochemical effects of long term consumption of high fat diet
WO2021130232A1 (en) Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms
Saeed Fenretinide's preventive effect on the development of osteoprosis in Cystic Fibrosis
Rosales-Corral et al. Research Article Alterations in Lipid Levels of Mitochondrial Membranes Induced by Amyloid-β: A Protective Role of Melatonin
Veinbergs The role of apolipoprotein E in neurodegeneration: Implications to Alzheimer's disease